Kobayashi S, Yamaguchi S, Okada K, Suyama N, Bokura K, Murao M, Tsunematsu T
3rd Department of Internal Medicine, Shimane Medical University, Japan.
Angiology. 1992 Oct;43(10):801-9. doi: 10.1177/000331979204301002.
The effect of nilvadipine, a newly developed calcium antagonist, on regional cerebral blood flow (rCBF) was investigated in 7 patients with chronic cerebral infarction. rCBF was measured by the 133Xenon inhalation method. Patients were given a single dose of 4 mg of nilvadipine after the first measurement of rCBF, and the second measurement was done one hour after the administration. All patients had hemiparesis and 2 of them had mild to moderate mental deterioration, but all patients could walk to the outpatient clinic by themselves.
(1) rCBF of the affected side significantly increased by 22.7% after single oral administration of nilvadipine (p < 0.05). The increase of rCBF was significantly marked in frontal regions of the affected hemispheres. (2) No significant changes in blood pressure or end tidal partial pressure of carbon dioxide were observed during the examination. These results indicate that nilvadipine has a potent selective vasodilatory action on the cerebral arteries in patients with cerebral infarction.
在7例慢性脑梗死患者中研究了新开发的钙拮抗剂尼伐地平对局部脑血流量(rCBF)的影响。rCBF通过吸入133氙的方法进行测量。在首次测量rCBF后,给患者单次服用4mg尼伐地平,给药1小时后进行第二次测量。所有患者均有偏瘫,其中2例有轻度至中度精神衰退,但所有患者均可自行步行至门诊。
(1)单次口服尼伐地平后,患侧rCBF显著增加22.7%(p<0.05)。rCBF的增加在患侧半球的额叶区域尤为明显。(2)检查期间未观察到血压或呼气末二氧化碳分压有显著变化。这些结果表明,尼伐地平对脑梗死患者的脑动脉具有强大的选择性血管舒张作用。